Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.61 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8338918 | 1.00 | CA2 (0.61) | CA2CA1HTTKDM4CALDH1A1 | |
| SCHEMBL11103451 | 0.90 | CA2 (0.71) | CA2CA1HTTKDM4CALDH1A1 | |
| SCHEMBL11103438 | 0.90 | CA2 (0.71) | CA2CA1HTTKDM4CALDH1A1 | |
| Valine SCHEMBL17036698 | 0.89 | CA2 (0.55) | CA2CA1HTTKDM4CALDH1A1 | |
| SCHEMBL8805714 | 0.84 | HTT (0.57) | CA2CA1HTTALDH1A1MAPT | |
| SCHEMBL1981446 | 0.83 | CA2 (0.63) | CA2CA1ALDH1A1GAACA12 | |
| SCHEMBL821456 | 0.83 | CA2 (0.63) | CA2CA1ALDH1A1GAACA12 | |
| SCHEMBL12302109 | 0.83 | CA2 (0.63) | CA2CA1ALDH1A1GAACA12 | |
| SCHEMBL30695663 | 0.83 | GAA (0.54) | HTTALDH1A1KDM4EGAAMEN1 | |
| SCHEMBL2796740 | 0.82 | CA1 (0.62) | CA2CA1ALDH1A1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344160-B2 | Pyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344160-B2 | Pyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344160-B2 | Pyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| EP-2346860-B1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-19 | — | — | EP | disclosed |
| EP-2346860-B1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2012-09-19 | — | — | EP | disclosed |
| CN-102245600-A | Pyrrolone melanin concentrating hormone receptor-1 antagonists | BRISTOL MYERS SQUIBB CO | 2011-11-16 | — | — | CN | disclosed |
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-11 | — | — | US | disclosed |
| EP-2346860-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2011-07-27 | — | — | EP | disclosed |
| WO-2010042674-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| WO-2010042674-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-04-15 | — | — | WO | disclosed |
| CN-1095593-A | The medicine of prevention and the disorder of treatment intestinal mucosa | OTSUKA PHARMA CO LTD (JP) | 1994-11-30 | — | — | CN | disclosed |
| EP-0549600-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1993-07-07 | — | — | EP | disclosed |
| WO-1992005163-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195986-A1 | PYRROLONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | CA2 4730/4885CA1 4801/4885HTT 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.